2024
P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
de la Fuente R, Peleg A, Litchman S, Gomez J, Doroshow D, Hirsch F, Veluswamy R, Marron T, Smith C, Rohs N, Rolfo C. P3.06D.04 Role of ctDNA Variant Allele Frequency in Predicting Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. Journal Of Thoracic Oncology 2024, 19: s323. DOI: 10.1016/j.jtho.2024.09.579.Peer-Reviewed Original Research
2017
BET inhibitors: a novel epigenetic approach
Doroshow DB, Eder JP, LoRusso PM. BET inhibitors: a novel epigenetic approach. Annals Of Oncology 2017, 28: 1776-1787. PMID: 28838216, DOI: 10.1093/annonc/mdx157.Peer-Reviewed Original ResearchConceptsBET inhibitorsHDAC inhibitorsEpigenetic agentsExtra-terminal motif (BET) proteinsImmune checkpoint inhibitorsEarly clinical trialsNovel epigenetic approachHistone deacetylaseZeste homolog 2BET proteinsMonotherapy activityCheckpoint inhibitorsTargeted agentsPreclinical dataClinical trialsDrug classesDrug combinationsSingle agentSolid tumorsPreclinical researchTumor cellsHomolog 2Lysine-specific demethylase 1Anticancer therapyInhibitors